Related by context. All words. (Click for frequent words.) 78 lymph node involvement 77 lymph node metastasis 75 distant metastasis 73 distant metastases 73 lymphovascular invasion 73 nodal metastases 72 micrometastases 72 axillary lymph nodes 72 metastases 72 locoregional recurrence 72 adenoma 72 mucinous 71 axillary nodes 71 EUS FNA 71 histologically 71 contralateral breast 71 PCa 71 advanced adenomas 70 breast carcinoma 70 micrometastasis 70 invasive carcinoma 70 liver metastases 70 histologic 70 urothelial carcinoma 70 pT2 70 nodal metastasis 70 intestinal metaplasia 70 FDG PET 70 renal cell carcinomas 70 extracapsular extension 69 metastatic lesions 69 mediastinal 69 node metastases 69 prostate carcinoma 69 neoplasms 69 lung nodules 69 malignant lesions 69 pCR 69 prostate cancer CaP 69 neoplasm 69 immunohistochemical staining 69 lymphadenectomy 69 advanced adenoma 69 adenocarcinomas 69 renal tumors 69 pancreatic adenocarcinoma 69 thyroglobulin 69 breast carcinomas 68 pulmonary metastases 68 adjuvant radiotherapy 68 lobular carcinoma 68 SUVmax 68 hepatocellular carcinomas 68 liver metastasis 68 nonmetastatic 68 prognostic factor 68 proximal colon 68 mediastinal lymph nodes 68 HGPIN 68 carcinomas 68 resected 68 colorectal neoplasms 68 biochemical recurrence 68 precursor lesions 68 resectable 68 metastatic lesion 68 histopathologic 67 ductal 67 axillary node 67 atypical hyperplasia 67 sarcomatoid 67 pT3 67 hamartomas 67 neoadjuvant therapy 67 lymphocytosis 67 axillary lymph node 67 mediastinoscopy 67 epithelial tumors 67 T1a 67 SLNB 67 lung metastases 67 F FDG PET 67 sentinel nodes 67 papillary 67 Hurthle cell 67 EGFR mutations 67 KRAS mutations 67 carcinoma 66 tumor recurrence 66 PSADT 66 ductal carcinomas 66 perineural invasion 66 seminal vesicle invasion 66 paragangliomas 66 gastric adenocarcinoma 66 Lymph node 66 sentinel lymph nodes 66 occult metastases 66 luminal 66 adenomas 66 hyperplastic 66 colorectal carcinoma 66 lymph node 66 metastatic tumors 66 sonographic findings 66 neoadjuvant chemotherapy 66 neoadjuvant 66 pathologic examination 66 cytoreductive surgery 66 lung metastasis 66 histological subtype 66 serous ovarian cancer 66 operable breast cancer 66 sentinel lymph node biopsy 66 cytokeratin 66 radical nephrectomy 66 CIN2 + 66 locoregional 66 lymphadenopathy 66 TIMP 66 ERBB2 65 preoperative chemotherapy 65 sentinel lymph node 65 invasive carcinomas 65 advanced neoplasia 65 FDG uptake 65 malignant nodules 65 histopathologic examination 65 CIN2 65 gadolinium enhanced 65 carcinoid tumor 65 metachronous 65 endosonography 65 immunohistochemical 65 neoplastic lesions 65 metastatic lymph nodes 65 sentinel node 65 tumoral 65 BRAF mutations 65 hypointense 65 mRNA expression 65 HER2 amplification 65 adenocarcinoma 65 underwent surgical resection 65 histologic subtype 65 adenomatous 65 situ LCIS 65 HER2 positive tumors 65 mammographically 65 hypermethylated 65 thyroid carcinoma 65 contralateral breast cancer 65 histologic examination 65 endometrioid 65 papillary renal cell carcinoma 65 malignant polyps 65 radical prostatectomy RP 65 ischemic lesions 65 endometrial carcinoma 65 scintigraphic 65 pelvic lymph nodes 65 Histological examination 65 colorectal adenoma 65 completely resected 65 thymoma 65 echogenicity 65 cytologically confirmed 65 HNSCC 65 underwent resection 65 hormone receptor negative 64 squamous 64 wedge resection 64 thyroid nodules 64 prostate cancer PCa 64 schwannomas 64 MALT lymphoma 64 sonographically 64 gastric carcinoma 64 neoplastic 64 curative resection 64 CIN3 64 neoplasia 64 invasive ductal 64 biochemical relapse 64 breast cancer subtypes 64 histopathological 64 ovarian carcinoma 64 BRCA1 mutation carriers 64 metastatic disease 64 adjuvant chemotherapy 64 grade cervical intraepithelial 64 estrogen receptor ER 64 prognostic significance 64 pulmonary nodules 64 serrated polyps 64 renal carcinoma 64 postoperative chemotherapy 64 supratentorial 64 pleomorphic 64 pancreatic carcinoma 64 cervical carcinoma 64 colorectal adenocarcinoma 64 invasive lobular 64 adenomatous polyps 64 mediastinum 64 rs# [002] 64 retroperitoneal 64 HER2 expression 64 Papillary 64 meningiomas 64 NMIBC 64 extracranial 64 GISTs 64 bone scintigraphy 64 breast lesions 64 adjuvant therapy 64 TIMP 1 64 prognostic factors 64 anaplastic 64 Subgroup analysis 64 atypia 64 splenic 64 elevated LDH 64 excisional biopsy 64 histologically confirmed 64 T2 weighted images 64 neoplasias 64 preoperative PSA 64 coronary stenosis 64 histologically proven 64 immunohistochemical analysis 64 cervical lymph nodes 64 conventional coronary angiography 64 debulking surgery 64 squamous histology 63 papillary thyroid carcinoma 63 MGUS 63 antigen PSA levels 63 stage IIIB 63 clinicopathologic 63 pelvic lymphadenectomy 63 HER2 negative 63 microsatellite instability 63 sonographic 63 adnexal mass 63 specific antigen PSA 63 GSTP1 63 medically inoperable 63 immunostaining 63 lymph node dissection 63 #.#ng/ml 63 T1c 63 peritumoral 63 hepatoma 63 axillary dissection 63 neoplastic cells 63 microvessel density 63 hamartoma 63 cytologic 63 pathologic diagnosis 63 neuroendocrine carcinoma 63 SPINK1 63 ductal lobular 63 #F FDG PET 63 lung adenocarcinomas 63 mesotheliomas 63 peritoneal carcinomatosis 63 peritoneal cancer 63 alkaline phosphatase ALP 63 scintigraphy 63 Metastatic 63 #p# [001] 63 ^ sup #m 63 malignant lymph nodes 63 univariate analysis 63 differentiated thyroid 63 BRAF V#E mutation 63 Histopathologic examination 63 intact parathyroid hormone 63 surgically resected 63 bladder cancers 63 epithelial ovarian 63 localized renal 63 FDG-PET/CT 63 polypoid 63 urine cytology 63 chemoradiotherapy 63 nonsmall cell lung cancer 63 metastatic 63 lobular 63 obstructive coronary artery 63 stenoses 63 thyroid carcinomas 63 esophageal carcinoma 63 morphologic 63 para aortic 63 upper endoscopy 63 hormone receptor status 63 B7 H3 63 perfusion defect 63 TP# mutations 63 catheter angiography 63 nondiabetic patients 63 histologic findings 63 IV NSCLC 63 serum PSA 63 KRAS wild 63 #F FDG 63 astrocytomas 62 BRCA2 mutation carriers 62 cholangiocarcinoma 62 ipsilateral 62 lobular carcinomas 62 transvaginal sonography 62 lung tumors 62 cell carcinomas 62 ipsilateral breast 62 carcinoid tumors 62 HER2 positive cancers 62 carcinoid 62 tumor necrosis 62 lymph nodes 62 hyperplastic polyps 62 ultrasonographic 62 malignant ovarian 62 colorectal neoplasia 62 papillary RCC 62 pathologic 62 malignancy 62 calculi 62 pituitary adenomas 62 intima media thickness 62 molecular subtypes 62 colorectal polyp 62 eosinophil count 62 grade gliomas 62 CaP 62 metastasis 62 gastric cancers 62 distal colon 62 adjuvant radiation 62 epithelial ovarian cancer 62 malignant prostate 62 clinicopathological features 62 intrahepatic 62 prostate adenocarcinoma 62 stage IIIA 62 extranodal 62 rebleeding 62 hepatocellular carcinoma 62 hydronephrosis 62 biopsy specimens 62 unresectable 62 axillary 62 immunoreactivity 62 malignant neoplasm 62 benign polyps 62 hypoechoic 62 Computed tomography 62 chemoembolization 62 cervical lymph node 62 endobronchial 62 uveal melanoma 62 cTnI 62 nephrectomy 62 pericardial effusion 62 plain radiographs 62 K ras mutations 62 appendiceal 62 oncologic outcomes 62 Immunohistochemical staining 62 cutaneous melanoma 62 benign lesions 62 EBRT 62 EGFR mutation 62 biopsy specimen 62 colorectal tumors 62 carotid stenosis 62 metastatic lung cancer 62 transesophageal echocardiography 62 serum creatinine levels 62 endometrial cancers 62 cardiac troponin T 62 cystectomy 62 PNET 62 parenchyma 62 leiomyomas 62 HRCT 62 chest radiographs 62 Immunohistochemical analysis 62 microcalcifications 62 taxane therapy 62 estrogen receptor negative 62 precancerous polyp 62 varices 62 lung nodule 62 HER2 receptor 62 TNF α 62 IGF 1R 62 invasive lobular carcinoma 62 hepatic metastases 62 gastrectomy 62 lung carcinomas 62 Subgroup analyzes 62 pheochromocytoma 62 Adenomas 62 unresectable tumors 61 multivariable analysis 61 thyroid nodule 61 hepatectomy 61 MYCN amplification 61 ductal cancer 61 ABCB1 61 Ki# 61 esophagectomy 61 cisplatin resistant 61 hyperintensity 61 parenchymal 61 carcinoids 61 esophagogastric junction 61 renal pelvis 61 KRAS mutation 61 TMPRSS2 ERG fusion 61 clinically detectable 61 bladder tumors 61 invasive ductal carcinoma 61 tumorigenicity 61 orthotopic 61 Tumor shrinkage 61 LHRH receptor positive 61 Helicobacter pylori infection 61 progesterone receptor negative 61 albuminuria 61 arteriography 61 intraductal 61 papillary carcinoma 61 multivariate analyzes 61 KRAS mutations occur 61 BRCA deficient 61 EpCAM 61 colorectal polyps 61 grade squamous intraepithelial 61 lymphocytic 61 Multivariate analysis 61 parathyroid 61 FDG PET imaging 61 colonic polyps 61 tumor histology 61 chest radiography 61 liver resection 61 hypoperfusion 61 transurethral resection 61 malignant lymphoma 61 prognostic indicator 61 poorer prognosis 61 TRUS 61 #q# [001] 61 SNP rs# [002] 61 axillary node dissection 61 malignant pleural mesothelioma 61 T1 weighted images 61 WT1 61 RTOG 61 percutaneous biopsy 61 metaplasia 61 paraganglioma 61 tumors 61 Histologic 61 cellularity 61 invasive coronary angiography 61 mCi 61 Figure 2C 61 stage IIIb IV 61 extramedullary 61 postoperative complication 61 HER2 overexpression 61 hilar 61 astrocytoma 61 microbleeds 61 PSA nadir 61 brain metastases 61 progesterone receptor PR 61 histological subtypes 61 metastatic tumor 61 gene polymorphisms 61 biliary tree 61 postoperative mortality 61 lobular cancer 61 extracolonic findings 61 hematopoietic cancers 61 RASSF1A 61 neuroblastoma tumors 61 NSCLC tumors 61 atypical ductal hyperplasia 61 sarcosine 61 promoter methylation 61 hepatocellular carcinoma HCC 61 malignant growths 61 MGd 61 recurrent glioblastoma multiforme 61 neuroendocrine tumors 61 pneumonectomy 61 Doppler sonography 61 ALND 61 endoscopic ultrasonography 61 liver histology 61 conventional angiography 61 BRCA mutation carriers 61 calcifications 61 nodular 61 histological 61 peritoneal 61 neoadjuvant treatment 61 TMPRSS2 ERG 61 vestibular schwannomas 61 troponin T 61 chest radiograph 61 peripheral blood mononuclear 61 resections 61 viable myocardium 61 prognostic variables 61 susceptibility loci 61 infarct size 61 fine needle aspiration 60 adnexal masses 60 ERCC1 60 radiographic findings 60 EBUS FNA 60 systolic dysfunction 60 tracer uptake 60 postoperative morbidity 60 metastatic malignant melanoma 60 computed tomographic 60 extracapsular 60 leiomyoma 60 gene amplification 60 hepatic lesions 60 elevated CRP 60 EpCAM expression 60 metastatic bladder 60 pancreatic prostate 60 TRUS biopsy 60 arthrography 60 biliary tract cancer 60 nephron sparing surgery 60 BRCA1 mutations 60 fallopian tube carcinoma 60 metastatic prostate cancer 60 small lymphocytic lymphoma 60 pancreatic lung 60 rs# [001] 60 tPSA 60 metastatic melanomas 60 troponins 60 Endometrial 60 ErbB2 positive 60 Kaplan Meier analysis 60 adrenalectomy 60 mesenteric 60 adjuvant therapies 60 epithelioid 60 chromosomal aberrations 60 FOLFOX4 60 vimentin 60 benign moles 60 lesions 60 total thyroidectomy 60 esophageal squamous cell carcinoma 60 IGFBP 60 TACE 60 NNRTI resistance 60 baseline LDH 60 cTnT 60 prostatic adenocarcinoma 60 ASCUS 60 H pylori 60 IDH1 mutation 60 clinically localized prostate 60 metastatic RCC 60 helical CT 60 follicular thyroid cancer 60 hematuria 60 IGF IR 60 germline mutations 60 salpingo oophorectomy 60 infarcts 60 Histologically 60 parathyroid carcinoma 60 radical cystectomy 60 malignant lesion 60 cytological 60 CIN3 + 60 colorectal cancer CRC 60 benign nodules 60 ovarian tumors 60 nodal dissection 60 DCIS lesions 60 missense mutations 60 rectal cancers 60 colorectal liver metastases 60 osteoid osteoma 60 computed tomographic scan 60 Radical prostatectomy 60 perioperative mortality 60 lactate dehydrogenase 60 androgen deprivation 60 GBM tumors 60 TRAIL R1 60 histologies 60 malignant fibrous histiocytoma 60 MAPK pathway 60 Circulating tumor cells 60 breast tumors 60 florbetaben 60 chromosome #p#.# 60 atheroma volume 60 p# biomarker 60 MR imaging 60 metastatic gastric 60 submucosa 60 angiographically 60 endometrial adenocarcinoma 60 cell adhesion molecule 60 lymphoid 60 recurrent NSCLC 60 prognostic marker 60 sCJD 60 bladder carcinoma 60 tHcy 60 nonmelanoma skin cancers 60 HAAH 60 BRAF mutation 60 hyperintense 60 FGFR2 60 ERalpha 60 coronary artery stenosis 60 hypopharynx 60 Plain radiographs 60 myocardial ischemia 60 thymectomy 60 lobectomy 60 cystatin C 60 myocardial viability 60 HER2 + 60 obscure gastrointestinal bleeding 60 basal cell carcinoma BCC 60 melanoma tumors 60 intratumoral 60 cystic lesions 60 urothelial 60 situ DCIS 60 premalignant 60 osteoid 60 resection 60 cathepsin B 60 cytologically 60 carcinoembryonic antigen 60 GPNMB 60 univariate 60 MAGE A3 60 axillary lymph node dissection 60 pheochromocytomas 60 Doxil ® 60 autoantibodies 60 colorectal carcinomas 60 duodenal 60 clinicopathological 60 Adjuvant chemotherapy 60 nonfatal MI 60 core needle biopsy 60 mutational status 60 glomerular 60 malignancies 60 K#R [002] 60 transitional cell carcinoma 60 normal karyotype 60 carotid artery thickness 60 carotid plaque 60 metastatic liver 60 TOP2A 60 locoregional disease 59 lung lesions 59 XELOX 59 cardiac troponin 59 untreated metastatic melanoma 59 MDCT 59 SLN biopsy 59 intraoperative complications 59 desmoplastic 59 noncardiac 59 TNF blocker therapy 59 node dissection 59 colon tumors 59 TET2 59 noncalcified 59 polyp recurrence 59 tumor shrinkage 59 prostate cancers 59 histologic subtypes 59 chemoradiation therapy 59 iodixanol 59 hypervascular 59 VATS lobectomy 59 ascites 59 ultrasonography 59 skeletal metastases 59 colorectal gastric 59 squamous carcinoma 59 T2 weighted MRI 59 colorectal tumor 59 medullary thyroid cancer 59 HG PIN 59 LVNC 59 atherosclerotic lesions 59 fluorodeoxyglucose positron emission tomography 59 seminomas 59 precancer 59 squamous cell carcinoma SCC 59 postoperative radiotherapy 59 MSH2 59 isoprostane 59 pre cancerous lesion 59 echogenic 59 intraepithelial neoplasia 59 antitumor effect 59 mammographic density 59 sentinel node biopsy 59 metastatic prostate 59 cerebral microbleeds 59 concurrent chemoradiation 59 EGFR receptor 59 histological diagnosis 59 LRP6 59 graft dysfunction 59 osteochondroma 59 Clusterin 59 CLL SLL 59 colorectum 59 grade dysplasia 59 oropharyngeal cancer 59 coronary angiography 59 Surgical resection 59 colon rectal 59 Recurrence Scores 59 ductal adenocarcinoma 59 pancreatic duct 59 pleural effusions 59 elevated ALT 59 urothelial cancer 59 chemoradiation 59 xenograft tumors 59 seminal vesicles 59 Squamous 59 liver transplant recipients 59 premalignant lesions 59 extrahepatic 59 iNOS 59 bronchogenic carcinoma 59 karyotype 59 duplex ultrasonography 59 p# mutations 59 subgroup analyzes 59 CR nPR 59 gemcitabine carboplatin 59 NGAL 59 abdominal computed tomography 59 preoperative radiotherapy 59 radiochemotherapy 59 metastatic pancreatic 59 carcinomatosis 59 castrate resistant 59 SCr 59 gefitinib Iressa 59 TGF β 59 ALK mutations 59 mRCC 59 cranial irradiation 59 chromosomal mutations 59 pre malignant lesions 59 pulmonary metastasis 59 intraobserver 59 relapsed MM 59 isoform 59 Carcinoma 59 cytoreductive nephrectomy 59 EGFR expression 59 resected pancreatic cancer 59 portal vein thrombosis 59 prostate carcinomas 59 Metastases 59 prostate tumor 59 endometrial hyperplasia 59 MACCE 59 antiangiogenic therapy 59 FGFR2 gene 59 antigen PSA 59 cell carcinoma 59 chromophobe 59 pretargeting 59 AGTR1 59 melanocytic nevi 59 IIIA NSCLC 59 genotypic resistance 59 Ultrasonography 59 lactate dehydrogenase LDH 59 TNM staging 59 ductal breast cancer 59 multimodality therapy 59 APOL1 59 leukocytosis 59 necrotic core 59 nephrogenic 59 TT genotype 59 coronary angiogram 59 cardiac dysfunction 59 CTEPH 59 surgically resectable 59 GSTM1 59 perfusion defects 59 subclinical hypothyroidism 59 transabdominal 59 Angiographic 59 seropositivity 59 prognostic indicators 59 pelvic ultrasound 59 cholelithiasis 59 PET CT scans 59 CDKN2A 59 uPAR 59 segmentectomy 59 venography 59 autoantibody 59 adenoma recurrence 59 anti JCV antibodies 59 femoral neck fracture 59 proteinuria 59 Sentinel node biopsy 59 lesion 59 prognostic markers 59 digital subtraction angiography 59 immunohistochemistry 59 K ras mutation 59 metastatic malignant 59 benign neoplasms 59 sleeve lobectomy 59 urothelium 59 lymphatic tissue 59 DLTs 59 seminoma 59 choroidal 59 #p#.# [002] 59 kidney cysts 59 adecatumumab 59 esophageal cancers 59 gated SPECT 59 metastatic colorectal 59 calcified plaques 59 heavily pretreated patients 59 serum calcium 59 lacunar 59 endometrial 59 PNH patients 59 KRAS oncogene 59 thromboembolic events 59 cytoreduction 59 acute aortic dissection 59 hormone receptor positive 59 vulvar intraepithelial neoplasia 58 basal cell skin 58 μmol L 58 HSCT 58 colorectal adenomas 58 platelet reactivity 58 hyperoxaluria 58 invasive ductal breast cancer 58 FDG PET scans 58 HBsAg 58 ^ Tc 58 IV melanoma 58 rs# [004] 58 intravesical therapy 58 gastric cancer 58 revascularization procedures 58 cervical intraepithelial neoplasia 58 dehiscence 58 histopathologic findings 58 cervical neoplasia 58 Response Evaluation Criteria 58 cancer mCRC 58 meningioma 58 S#A# [002] 58 dacarbazine DTIC 58 HBeAg 58 nodular melanoma 58 perioperative morbidity 58 F FDG uptake 58 lymphoid cells 58 % CI #.#-#.# [007] 58 FGFR1 58 nonischemic 58 oropharyngeal 58 HER2 positive metastatic breast 58 lymph node removal 58 contralateral 58 5FU 58 BRCA2 carriers 58 amyloid deposition 58 sunitinib Sutent 58 preoperative staging 58 P = .# 58 R0 resection 58 IL#B 58 definite stent thrombosis 58 visceral metastases 58 follicular lymphomas 58 VEGF expression 58 elevated troponin 58 HBeAg negative 58 activating mutations 58 sonographically guided 58 FOLPI 58 chemosensitivity 58 HPV# 58 liposarcoma 58 synovial 58 IgG antibodies 58 Computed tomographic 58 malignant neoplasms 58 prognostic biomarker 58 MLH1 58 carotid bruit 58 ovarian pancreatic 58 genetic polymorphisms 58 dysplastic 58 cerebrospinal fluid CSF 58 HER2 positive 58 explants 58 INCB# [003] 58 xenografts 58 ADPKD 58 specific antigen 58 androgen receptor AR 58 macroalbuminuria 58 xenograft models 58 antibody titer 58 polypoid lesions 58 thoracoscopic lobectomy 58 NSCLC 58 Recurrence Score 58 biochemical marker 58 endocrine therapy 58 LV dysfunction 58 gemcitabine Gemzar 58 LV ejection fraction 58 annexin V 58 APOE e4 58 annexin 58 radiographically 58 hyperintense lesions 58 nasopharyngeal carcinoma 58 hyperechoic 58 adrenal masses 58 HIV RNA 58 polyposis 58 mesothelin 58 renal cell carcinoma 58 recurrent metastatic 58 Ultrasonographic 58 oligodendroglioma 58 fallopian tube cancers 58 prophylactic cranial irradiation 58 GSTT1 58 radioiodine therapy 58 resectable pancreatic cancer 58 intestinal polyps 58 seminal vesicle 58 parathyroidectomy 58 HER2 gene 58 computed tomographic scans 58 histologic diagnosis 58 white matter hyperintensities 58 hypercoagulable 58 myocardial perfusion 58 pretransplant 58 PSA velocity 58 tumor biopsies 58 CsA 58 bleomycin 58 fluorescein angiography 58 CT angiography 58 lymphomas 58 myometrium 58 IgA deficiency 58 gastric cardia 58 haematopoietic 58 squamous cell lung cancer 58 spiral computed tomography 58 radionuclide imaging 58 PGDH